Targeted Therapy (Investigational)
44 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (Investigational) (44)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Devimistat |
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) | Solid Tumour | ||
|
Molecule
Devimistat
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
||||
Elenestinib |
Next-Generation KIT D816V Inhibitor | Hematologic | ||
|
Molecule
Elenestinib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Next-Generation KIT D816V Inhibitor |
||||
Elimusertib |
DNA Damage Response Inhibitor | Solid Tumour | ||
|
Molecule
Elimusertib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
||||
Emavusertib |
IRAK4 Kinase Inhibitor | Hematologic | ||
|
Molecule
Emavusertib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
IRAK4 Kinase Inhibitor |
||||
Enmd-2076 |
Polo-Like / Aurora Kinase Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Enmd-2076
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
||||
Epacadostat |
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) | Solid Tumour | ||
|
Molecule
Epacadostat
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
||||
Gartisertib |
DNA Damage Response Inhibitor | Solid Tumour | ||
|
Molecule
Gartisertib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
||||
Guadecitabine |
Hypomethylating / Investigational Agent | Hematologic (MDS/AML) | ||
|
Molecule
Guadecitabine
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic (MDS/AML)
Drug Class / Mechanism
Hypomethylating / Investigational Agent |
||||
IACS-010759 |
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) | Solid Tumour | ||
|
Molecule
IACS-010759
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
||||
Ianalumab |
Targeted Protein Degrader | Hematologic | ||
|
Molecule
Ianalumab
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
||||
Ilorasertib |
Polo-Like / Aurora Kinase Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Ilorasertib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
||||
Indoximod |
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) | Solid Tumour | ||
|
Molecule
Indoximod
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
||||
DevimistatTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
|
ElenestinibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Next-Generation KIT D816V Inhibitor |
|
ElimusertibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
|
EmavusertibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
IRAK4 Kinase Inhibitor |
|
Enmd-2076Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
|
EpacadostatTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
|
GartisertibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
|
GuadecitabineTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic (MDS/AML)
Drug Class / Mechanism
Hypomethylating / Investigational Agent |
|
IACS-010759Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
|
IanalumabTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
|
IlorasertibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
|
IndoximodTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
|